Skip to main content
Medic Debate
- The Antidote to Medical Misinformation and Propaganda!
Languages
Dansk
Nederlands
English
Français
Deutsch
Italiano
Español
Kiswahili
Svenska
Search form
Search
Main menu
Home
Search
About us
Books
Category Search
Log In
Recent posts
Treatment Protocols
You are here
Home
Phase 1 Clinical trial
Items per page
5
10
20
40
60
100
Title
Average Rating
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients.
50.00%
A phase I study of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
40.00%
A Phase I study of the safety of the nutritional supplement, active hexose correlated compound, AHCC, in healthy volunteers.
50.00%
A phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination..............
70.00%
A phase I trial of tumor-associated antigen-pulsed dendritic cell immunotherapy for patients with brain stem glioma and glio....
60.00%
A pilot study for treatment of COVID-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatment-registered clinical trial
70.00%
A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer.
Anterior Cingulate Desynchronization and Functional Connectivity with the Amygdala During a Working Memory Task Predict Rapid An
80.00%
Antitumor activity of patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells: In vitro results and cli
70.00%
Circulating tumor and endothelial cells as pharmacodynamic biomarkers in a phase I clinical trial of intravenous bevacizumab....
40.00%
Clinical studies of Ukrain in healthy volunteers (phase 1).
60.00%
Controlled clinical evaluations of chlorine dioxide, chlorite and chlorate in man.
70.00%
Correlation between prior therapeutic dendritic cell vaccination and the outcome of patients with metastatic melanoma treated...
30.00%
Final results of a pharmacokinetic (PK) and pharmacodynamic (PD) phase I trial of ARQ 197 incorporating dynamic contrast........
60.00%
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.
30.00%
Metabolic modulation of glioblastoma with dichloroacetate.
90.00%
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients ....
80.00%
Metronomic schedule of temozolomide with conventional dose of cisplatin in metastatic melanoma. Sub-category: Melanoma Categor
90.00%
Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma.
60.00%
Oral metronomic cyclophosphamide in elderly with metastatic melanoma.
70.00%
Outpatient administration of high-dose methotrexate for osteosarcoma treatment in Brazil.
30.00%
Pharmacology and safety factors affecting use of flat (rather than weight-based) dosing of tesetaxel, an orally administered....
30.00%
Phase I adjuvant trial of multi-epitope p53 vaccine for patients with squamous cell carcinoma of the head and neck (SCCHN): A pr
45.00%
Phase I study of sunitinib malate continuously dosed and standard-infusion gemcitabine in solid tumors.
70.00%
Phase I trial of capecitabine (Cap) and gemcitabine (G) with concurrent radical radiotherapy in locally advanced pancreatic ca..
40.00%
Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer.
70.00%
Pilot Study of Sentinel-Node-Based Adoptive Immunotherapy in Advanced Colorectal Cancer.
90.00%
Removed because of suspicion of scientific fraud: Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF.
10.00%
Removed from Pubmed because of suspiion of scientific fraud: Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF.
75.00%
Therapeutic vaccination against advanced pancreatic cancer by autologous dendritic cells pulsed with a MUC1 peptide: Preclinic..
60.00%
Treatment of advanced pancreatic cancer with opioid growth factor: phase I.
90.00%
Tumor therapy with Amanita phalloides (death cap): stabilization of B-cell chronic lymphatic leukemia.
90.00%